TW202319054A - Nlrp3調節劑 - Google Patents
Nlrp3調節劑 Download PDFInfo
- Publication number
- TW202319054A TW202319054A TW111124256A TW111124256A TW202319054A TW 202319054 A TW202319054 A TW 202319054A TW 111124256 A TW111124256 A TW 111124256A TW 111124256 A TW111124256 A TW 111124256A TW 202319054 A TW202319054 A TW 202319054A
- Authority
- TW
- Taiwan
- Prior art keywords
- membered
- alkyl
- ring
- pharmaceutically acceptable
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216446P | 2021-06-29 | 2021-06-29 | |
| US63/216,446 | 2021-06-29 | ||
| US202263320155P | 2022-03-15 | 2022-03-15 | |
| US63/320,155 | 2022-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202319054A true TW202319054A (zh) | 2023-05-16 |
Family
ID=84692056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111124256A TW202319054A (zh) | 2021-06-29 | 2022-06-29 | Nlrp3調節劑 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240327413A1 (https=) |
| EP (1) | EP4362946A4 (https=) |
| JP (1) | JP2024529839A (https=) |
| TW (1) | TW202319054A (https=) |
| WO (1) | WO2023278438A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| LT4363406T (lt) | 2021-07-02 | 2025-12-29 | Astrazeneca Ab | Nlrp3 inflamasomų inhibitoriai |
| TW202319055A (zh) | 2021-07-21 | 2023-05-16 | 日商安斯泰來製藥股份有限公司 | 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物 |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
| CR20240093A (es) | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| WO2023088856A1 (en) * | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| JP2025511199A (ja) * | 2022-03-31 | 2025-04-15 | ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド | Ｎｌｒｐ３インフラマソーム阻害剤 |
| US20260015357A1 (en) * | 2022-07-01 | 2026-01-15 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| CN120569372A (zh) * | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| KR20250151413A (ko) * | 2023-01-31 | 2025-10-21 | 얀센 파마슈티카 엔브이 | NLRP3 억제제로서의 이미다조[1,2-d][1,2,4]트라이아진 |
| KR20250134147A (ko) | 2023-01-31 | 2025-09-09 | 얀센 파마슈티카 엔브이 | NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진 |
| WO2024160694A1 (en) * | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS |
| TW202448892A (zh) * | 2023-04-17 | 2024-12-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠合噠嗪類衍生物及其用途 |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026082103A1 (zh) * | 2024-10-16 | 2026-04-23 | 青岛博森泰科技有限公司 | 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途 |
| WO2026082092A1 (zh) * | 2024-10-16 | 2026-04-23 | 青岛博森泰科技有限公司 | 一种nlrp3抑制剂用于治疗炎症的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919957D0 (en) * | 1999-08-23 | 1999-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| WO2006004589A2 (en) * | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| JP7595642B2 (ja) * | 2019-07-17 | 2024-12-06 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
-
2022
- 2022-06-28 EP EP22834059.2A patent/EP4362946A4/en active Pending
- 2022-06-28 US US18/574,530 patent/US20240327413A1/en active Pending
- 2022-06-28 WO PCT/US2022/035306 patent/WO2023278438A1/en not_active Ceased
- 2022-06-28 JP JP2023580379A patent/JP2024529839A/ja active Pending
- 2022-06-29 TW TW111124256A patent/TW202319054A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024529839A (ja) | 2024-08-14 |
| EP4362946A1 (en) | 2024-05-08 |
| WO2023278438A1 (en) | 2023-01-05 |
| US20240327413A1 (en) | 2024-10-03 |
| EP4362946A4 (en) | 2025-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202319054A (zh) | Nlrp3調節劑 | |
| JP7595642B2 (ja) | Ｎｌｒｐ３モジュレーター | |
| US11603375B2 (en) | NLRP3 modulators | |
| TW202345834A (zh) | Nlrp3調節劑 | |
| AU2020312800B2 (en) | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) | |
| KR20080110905A (ko) | 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도 | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| CN117881401A (zh) | Nlrp3调节剂 | |
| WO2025059069A1 (en) | Nlrp3 modulators | |
| WO2025064325A1 (en) | Gpr35 modulators | |
| EA049038B1 (ru) | Модуляторы nlrp3 |